Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis.

Guo W, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghirami G, Giancotti FG.

Cell. 2006 Aug 11;126(3):489-502.

2.

Co-opted integrin signaling in ErbB2-induced mammary tumor progression.

Carraway KL 3rd, Sweeney C.

Cancer Cell. 2006 Aug;10(2):93-5. Review.

3.

ErbB2 makes beta 4 integrin an accomplice in tumorigenesis.

Muthuswamy SK.

Cell. 2006 Aug 11;126(3):443-5. Review.

4.

Developmental timing of activated erbB2 expression plays a critical role in the induction of mammary tumors.

Andrechek ER, Muller WJ.

Cell Cycle. 2004 Sep;3(9):1111-3. Epub 2004 Sep 1. Review.

PMID:
15326381
5.

Sequestration and segregation of receptor kinases in epithelial cells: implications for ErbB2 oncogenesis.

Carraway CA, Carraway KL.

Sci STKE. 2007 Apr 10;2007(381):re3. Review.

PMID:
17426346
6.

Signal transduction in mammary tumorigenesis: a transgenic perspective.

Dankort DL, Muller WJ.

Oncogene. 2000 Feb 21;19(8):1038-44. Review.

PMID:
10713687
7.

Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.

Chen FL, Xia W, Spector NL.

Clin Cancer Res. 2008 Nov 1;14(21):6730-4. doi: 10.1158/1078-0432.CCR-08-0581. Review.

8.

Targeting integrin beta4 for cancer and anti-angiogenic therapy.

Giancotti FG.

Trends Pharmacol Sci. 2007 Oct;28(10):506-11. Epub 2007 Sep 5. Review.

PMID:
17822782
9.

ErbB2 activation and signal transduction in normal and malignant mammary cells.

Hynes NE.

J Mammary Gland Biol Neoplasia. 1996 Apr;1(2):199-206. Review.

PMID:
10887493
10.

Insights from transgenic mouse models of ERBB2-induced breast cancer.

Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ.

Nat Rev Cancer. 2007 May;7(5):389-97. doi: 10.1038/nrc2127. Epub 2007 Apr 19. Review.

PMID:
17446858
11.

The roles of integrin β4 in vascular endothelial cells.

Wang L, Dong Z, Zhang Y, Miao J.

J Cell Physiol. 2012 Feb;227(2):474-8. doi: 10.1002/jcp.22769. Review.

PMID:
21465468
12.

Myc and mammary cancer: Myc is a downstream effector of the ErbB2 receptor tyrosine kinase.

Hynes NE, Lane HA.

J Mammary Gland Biol Neoplasia. 2001 Jan;6(1):141-50. Review.

PMID:
11467449
13.

Fgf-3, an oncogene in murine breast cancer.

Dickson C, Fantl V.

Cancer Treat Res. 1994;71:331-43. Review. No abstract available.

PMID:
7946957
14.

Tenascin-C induced signaling in cancer.

Orend G, Chiquet-Ehrismann R.

Cancer Lett. 2006 Dec 8;244(2):143-63. Epub 2006 Apr 24. Review.

PMID:
16632194
15.

ErbB receptors and cell polarity: new pathways and paradigms for understanding cell migration and invasion.

Feigin ME, Muthuswamy SK.

Exp Cell Res. 2009 Feb 15;315(4):707-16. doi: 10.1016/j.yexcr.2008.10.034. Epub 2008 Nov 5. Review.

PMID:
19022245
16.

Molecular mediators of cell death in multistep carcinogenesis: a path to targeted therapy.

Spurgers KB, Chari NS, Bohnenstiehl NL, McDonnell TJ.

Cell Death Differ. 2006 Aug;13(8):1360-70. Epub 2006 Jun 9. Review.

17.

ErbB2 signaling at the crossing between heart failure and cancer.

Vermeulen Z, Segers VF, De Keulenaer GW.

Basic Res Cardiol. 2016 Nov;111(6):60. doi: 10.1007/s00395-016-0576-z. Epub 2016 Sep 5. Review.

18.

Introduction to supramolecular complex formation in cell signaling and disease.

Leyton L, Quest AF.

Biol Res. 2002;35(2):117-25. Review. No abstract available.

PMID:
12415728

Supplemental Content

Support Center